Contrast Agents Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Summary
GlobalData's Medical Devices sector report, “Contrast Agents Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update provides comprehensive information about the Contrast Agents pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Contrast agents are substances applied in medical imaging to increase visibility of internal structures like organs, blood vessels, and other tissues. Before the imaging operation, they are frequently injected into the body or taken orally to boost contrast and enhance the visibility of specific structures.
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Extensive coverage of the Contrast Agents under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Contrast Agents and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of Contrast Agents under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product’s current stage of development, territory and estimated launch date
Introduction
Contrast Agents Overview
Products under Development
Contrast Agents - Pipeline Products by Stage of Development
Table Contrast Agents - Pipeline Products by Stage of Development
Table Contrast Agents - Pipeline Products by Stage of Development
Contrast Agents - Pipeline Products by Segment
Table Contrast Agents - Pipeline Products by Segment
Table Contrast Agents - Pipeline Products by Segment
Contrast Agents - Pipeline Products by Territory
Table Contrast Agents - Pipeline Products by Territory
Table Contrast Agents - Pipeline Products by Territory
Contrast Agents - Pipeline Products by Regulatory Path
Table Contrast Agents - Pipeline Products by Regulatory Path
Table Contrast Agents - Pipeline Products by Regulatory Path
Contrast Agents - Pipeline Products by Estimated Approval Date
Table Contrast Agents - Pipeline Products by Estimated Approval Date
Table Contrast Agents - Pipeline Products by Estimated Approval Date
Contrast Agents - Ongoing Clinical Trials
Table Contrast Agents - Ongoing Clinical Trials
Table Contrast Agents - Ongoing Clinical Trials
Contrast Agents - Pipeline Products under Development by Companies
Contrast Agents Companies - Pipeline Products by Stage of Development
Table Contrast Agents Companies - Pipeline Products by Stage of Development
Contrast Agents - Pipeline Products by Stage of Development
Table Contrast Agents - Pipeline Products by Stage of Development
Table ADx Nanoparticle - A Phase 1, Controlled, Open-label, Single Dose, Dose-escalation, Clinical Proof-of-concept Study of MRI Enhanced With ADx-001 (DSPE-DOTA-Gd Liposomal Injection) in Patients with Brain Amyloid Deposits as Demonstrated by Amyloid PET
Table AMDX-2011P - A Phase 2, Open-Label Study of AMDX-2011P as a Retinal Tracer in Participants With Cerebral Amyloid Angiopathy (CAA)
Table Fluorescent Retinal Contrast Agent - Parkinson's Disease - Prospective Randomized Open, Blinded Endpoint (PROBE) Study of AMDX-2011P as a Retinal Tracer in Subjects with Neurodegenerative Diseases Associated with Amyloidogenic Proteinopathy
Antaros Medical AB Company Overview
Antaros Medical AB Pipeline Products & Ongoing Clinical Trials Overview
Table Antaros Medical AB Pipeline Products & Ongoing Clinical Trials Overview
Table GE HealthCare Technologies Inc - Ongoing Clinical Trials Overview
Table Manganese-Based Macrocyclic Magnetic Resonance Imaging (MRI) Contrast Agent - A Phase I Study to Assess the Safety Profile of Injectable Manganese Contrast Agent
Georgia State University Company Overview
Georgia State University Pipeline Products & Ongoing Clinical Trials Overview
Table Georgia State University Pipeline Products & Ongoing Clinical Trials Overview
Table Protein Contrast Agent - Product Status
Table Protein Contrast Agent - Product Description
H. Lee Moffitt Cancer Center & Research Institute Inc Company Overview
H. Lee Moffitt Cancer Center & Research Institute Inc Pipeline Products & Ongoing Clinical Trials Overview
Table H. Lee Moffitt Cancer Center & Research Institute Inc Pipeline Products & Ongoing Clinical Trials Overview
Table Fluorescent Probe - Pancreatic Cancer - Product Status
Table Fluorescent Probe - Pancreatic Cancer - Product Description
Hana Pharm Co Ltd Company Overview
Hana Pharm Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table Hana Pharm Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table HNP-2006 - Product Status
Table HNP-2006 - Product Description
Harvard University Company Overview
Harvard University Pipeline Products & Ongoing Clinical Trials Overview
Table Harvard University Pipeline Products & Ongoing Clinical Trials Overview
Table Hyperpolarized MRI Contrast Agent - Product Status
Table MB-102 - A Pilot Study to Assess the Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
Table MB-102 - An Open Label, Multi-Center, Safety and Pharmacokinetic Bridging Study of MB-102 (Relmapirazin) and the Use of the MediBeacon Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring in Normal and Renal Compromised Subjects for the Evaluation of Kidney Function
Memorial Sloan Kettering Cancer Center Company Overview
Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview
Table Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview
Table Zr-89-Transferrin PET Radiotracer - Product Status
Table Zr-89-Transferrin PET Radiotracer - Product Description
Microbial Medical Inc Company Overview
Microbial Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table MRI Contrast Agent - Prostate Cancer (MT218) - An Open-label Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent (MT218) in Prostate Cancer Patients
Monash University Company Overview
Monash University Pipeline Products & Ongoing Clinical Trials Overview
Table Monash University Pipeline Products & Ongoing Clinical Trials Overview
Table On Target Laboratories LLC - Ongoing Clinical Trials Overview
Table Cytalux - A Pilot Study of Near-Infrared Imaging Using the Novel Imaging Agent Cytalux for Adolescent Patients With Metastatic Osteosarcoma Undergoing Pulmonary Metastasectomy
Table Cytalux - An Investigator Sponsored Study to Investigate the Safety and Efficacy of CYTALUX (PAFOLACIANINE) INJECTION for the Intraoperative Imaging of Prostate Cancer
Table Cytalux - Near-infrared Fluorescence Molecular Imaging of Adalimumab-800CW to Elucidate the Drug Distribution Throughout Inflamed Tissue in Inflammatory Bowel Disease and Rheumotoid Arthritis
OncoNano Medicine Inc Company Overview
OncoNano Medicine Inc Pipeline Products & Ongoing Clinical Trials Overview
Table OncoNano Medicine Inc - Ongoing Clinical Trials Overview
Table Pegsitacianine Intraoperative Imaging Agent - A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
Table Hexvix - A Pilot, Real-world Evidence Study of Hexvix in Bladder Cancer Patients of Hainan Province of China
Table Hexvix - A Study to Evaluate the Use of Blue Light Cystoscopy Among Non-muscle Invasive Bladder Cancer Subjects and Outcomes in an Equal Access Setting: A Propensity Scored Matched Analysis
Table Hexvix - Blue Light Cystoscopy with Cysview Registry
Table Hexvix - Flexible Blue Light Cystoscopy with Hexaminolevulinate Provides Opportunity to Finalize Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer in the Outpatient Clinic
Table Hexvix - Non-inferiority, Phase IV, Open-label, Randomized Controlled Trial of Vesical Imaging- Reporting and Data System (VI-RADS) Followed by Primary Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) Versus Conventional White-light TURBT Plus Repeated-TURBT (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs) Candidate for Second Look and Resection
Table Hexvix - Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
Table SBI Pharmaceuticals Co Ltd - Ongoing Clinical Trials Overview
Table Gleolan - A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Suspected Newly Diagnosed or Recurrent Epithelial Ovarian Cancer
Table Maraciclatide - Rheumatoid Arthritis - An Observational Study Exploring the Value 99mMaracticaltide Imaging for Predicting Outcomes for Patients With Rheumatoid Arthritis Undergoing Tapering of Therapy
SurgiMab SAS Pipeline Products & Ongoing Clinical Trials Overview
Table SurgiMab SAS Pipeline Products & Ongoing Clinical Trials Overview
Table SGM-101 - Product Status
Table SGM-101 - Product Description
Table SGM-201 - Product Status
Table SGM-201 - Product Description
Table SGM-301 - Product Status
Table SGM-301 - Product Description
Table SurgiMab SAS - Ongoing Clinical Trials Overview
Table SGM-101 - A Performance Study of SGM-101, a Fluorochrome-labeled Anti-carcinoembryonic Antigen Monoclonal Antibody for Fluorescence-guided Imaging to Determine Local Extent and Resectability During Surgical Resection of Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment
Table SGM-101 - Multicenter, Open-label, Randomized, Controlled, Parallel Arms Clinical Study on Performance of SGM-101, a Fluorochrome-labeled Anti-CEA Monoclonal Antibody, for Delineation of Primary/Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
Table VGT-309 - A Phase 2, Multi-center, Open-label Study to Evaluate the Safety and Efficacy of VGT-309, a Tumor-Targeted, Activatable Fluorescent Imaging Agent, in Subjects Undergoing Surgery for Cancer in the Lung
Table VGT-309 - A Phase II, Open-label Study to Evaluate the Safety, Efficacy, Dosing, and Timing of VGT-309, a Tumor-Targeted, Activatable Fluorescent Imaging Agent for the Intraoperative Identification of Lung Cancer
Table VGT-309 - Pilot Open Label Study to Determine the Safety and Efficacy of Fluorescent Probe, VGT-309, to Identify Cancerous Colorectal Lesions During White-Light and Fluorescence Augmented Colonoscopy
May 22, 2024: HKU Engineering Team Enhances Stereotactic Neurosurgery Precision Using MRIGuided Multi-Stage Robotic Positioner
May 14, 2024: Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update
May 08, 2024: Polarean's Xenon MRI to be Featured at Upcoming ATS 2024 Conference
May 07, 2024: Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024
May 07, 2024: University Hospitals Cleveland, Siemens Healthineers in New Alliance to Improve Oncology, Cardiovascular and Neurovascular Care for Patients
May 06, 2024: JNM Supplement Highlights Nuclear Medicine Innovation in China
May 02, 2024: Ascelia Pharma Successfully Meets Primary Endpoint With Strong Headline Results in Orviglance Phase 3 Study
Apr 30, 2024: Bladder Cancer: pivotal trial results and new real-world evidence, to be presented at AUA 2024, demonstrate improved diagnostic and clinical outcomes with blue light cystoscopy
Apr 28, 2024: CYTALUX Real-World Experience Presented at the American Association for Thoracic Surgery 104th Annual Meeting
Apr 17, 2024: Korean, US Researchers Develop New Dual Fluorescence Imaging Technique for Precision Lung Cancer Surgery
Apr 16, 2024: Clinical Trial Looks to Improve Treatment of Early-Stage Breast Cancer
Apr 12, 2024: Hengrui Pharmaceutical's Three Innovative Drugs HRS-9231 Injection, SHR-4597 Inhalation and SHR-2173 Injection Were Approved for Clinical Trials
Apr 08, 2024: European Association of Urology (EAU) 2024 Congress Features New Data on Modern Technology Use in Bladder Cancer Care
Apr 01, 2024: UC San Diego Receives $6.7M to Develop Whole-Body Inflammation Imaging
Mar 28, 2024: New Publication: Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy
Mar 25, 2024: Sino Biopharmaceutical: Voluntary Announcement Approval for Marketing of Iopromide Injection
Mar 20, 2024: MD Anderson Research Highlights for March 20, 2024
Mar 19, 2024: MINDSET Integrated And US Radiology Specialists Announce Strategic Agreement On Brain Injury Assessment
Mar 14, 2024: Subtle Medical Supports R01 Grant for AI-Powered Pediatric Imaging Secured with Researchers at Boston Children's Hospital and Massachusetts General Hospital
Mar 05, 2024: NX Development is Granted Orphan-Drug Designation Status by US FDA for Gleolan in Ovarian and Related Cancers
Feb 29, 2024: Medtronic Files ITC Action Against Axonics to Stop Unauthorized Use of Medtronic Innovations
Feb 28, 2024: Collaborative Development of AI Technology to Precisely Extract Areas Suspected of Glioma from MRI Images
Feb 08, 2024: New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
Feb 07, 2024: Isotopia USA is thrilled to announce its new partnership with E Solutions and Comfort Systems USA to build out its North American headquarters and US GMP manufacturing center
Jan 29, 2024: Photocure Partner Asieris Presented Clinical Trial and Real-World Data on Hexvix in China at ASCO GU 2024
Jan 29, 2024: Asieris Releases Phase III Clinical Study and Real-World Research Data for APL-1706, a Bladder Cancer Diagnosis and Management Drug, at the 2024 ASCO-GU
Jan 28, 2024: Vergent Bioscience Presents Phase 2 Data Showing VGT-309 Visualizes Tumors in the Lung During Surgery
Jan 19, 2024: Innovative Imaging solution offers potential breakthrough in endometriosis detection
Jan 12, 2024: Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results
Jan 03, 2024: Case Western Reserve Researchers Land $1.1m National Science Foundation Grant to Advance Safer, Faster and Less Expensive Medical-Imaging Technology
Dec 19, 2023: Study Discovers Novel Biomarker for Vascular Aging and Neurodegeneration
Dec 18, 2023: Heart Vest Could Help Predict Sudden Cardiac Death Risk
Dec 15, 2023: Spago Nanomedical Reports Positive Top Line Data from Clinical Phase IIa Study SPAGOPIX-02 In Patients with Endometriosis
Dec 15, 2023: Photocure Partner Asieris To Present Unpublished Clinical Trial and Real-World Data on Hexvix in China at ASCO GU 2024
Dec 13, 2023: Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense HER2 Imaging Agent
Dec 13, 2023: Vergent Bioscience Initiates Phase 2, Multi-Center VISUALIZE Study Evaluating Efficacy of Tumor-targeted Fluorescent Imaging Agent VGT-309 in Lung Cancer Surgeries
Dec 12, 2023: Bracco wins EU approval for MRI contrast agent
Dec 11, 2023: Guerbet announces marketing authorisation approval of Elucirem (Gadopiclenol) in the European Union
Dec 01, 2023: SUO 2023 Meeting: New Real World Evidence shows Significant Decrease in Risk of Bladder Cancer Recurrence with Blue Light Cystoscopy
Nov 27, 2023: Guerbet to Spotlight Diagnostic Solutions at the 2023 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting
Nov 22, 2023: Bayer Championing Advancements in Radiology Pipeline and Accelerating AI Innovation
Nov 22, 2023: Novel MRI Reveals Brain Changes in Long-COVID Patients
Nov 20, 2023: Biggest Prostate Cancer Screening Trial in Decades to Start in UK
Nov 14, 2023: Amydis Receives $3.4 million NIH Commercialization Readiness Pilot Grant Award to Map Heterogeneity of Alzheimer's Diseases in Human Clinical Trial Using Novel Retinal Tracer
Nov 06, 2023: CEPI and University of Oxford advance vaccine work against potentially deadly Arenaviruses
Nov 02, 2023: Guerbet to Spotlight Diagnostic and Interventional Solutions at the 2023 Radiological Society of North America (RSNA) Scientific Assembly and Annual Meeting
Nov 02, 2023: Amydis Launches Phase 2 Glaucoma Clinical Program Using Novel Retinal Tracer to Detect Amyloid Beta
Oct 25, 2023: Ligand To Report Third Quarter 2023 Financial Results On November 8
Oct 19, 2023: Hyperfine to Announce Third Quarter Financial Results on November 9, 2023
Oct 16, 2023: Researchers Develop Innovative Technique for Distinguishing Tumor from Normal Tissue
Oct 12, 2023: Positive Results for Hexvix Phase III Clinical Trial in China Presented at the SIU 2023 Congress
Oct 12, 2023: Vueway (Gadopiclenol) Receives Positive CHMP Opinion
Oct 09, 2023: Imagion Presents Ovarian Cancer Data at AACR Conference
Oct 09, 2023: France Concludes There Is Insignificant Cost Difference Between White Light and Blue Light Cystoscopy Use When Applying Ccafu Guidelines
Oct 07, 2023: Photocure Partner Asieris to Present First Results for Its Hexvix Phase III Clinical Trial in China at the SIU 2023 Annual Meeting
Oct 04, 2023: Northwestern's First Woman Director of Bands to Retire
Oct 02, 2023: Human Disease Simulator Lets Scientists Choose Their Own Adventure
Sep 21, 2023: Bracco Imaging Announces Global Agreement With Subtle Medical
Sep 15, 2023: New Test Helps Drug Discoverers Identify Future Cancer Treatments
Sep 14, 2023: Voyageur Pharmaceuticals Achieves Milestone in the Development of HDXBa Barium Contrast Media
Sep 13, 2023: Multi-Institutional Center for the Mechanical Control of Chemistry Awarded $20M CCI Grant
Sep 11, 2023: Phase 2 Data Demonstrate Potential of Vergent Biosciences' Tumor-Targeted Fluorescent Imaging Agent to Improve Success of Lung Cancer Surgeries
Sep 08, 2023: Polarean Imaging : Partnership with VIDA To Streamline Adoption of Advanced MRI of the Lungs
Sep 08, 2023: Polarean Partners with VIDA to Streamline Adoption of Advanced MRI of the Lungs